m6A-centered Drug Response Information

General Information of the Drug (ID: M6APDG04265)
Name
Faricimab
Synonyms
RO6867461; RG7716
    Click to Show/Hide
Status
Phase 3
TTD Drug ID
D9MWL4
Target Gene(s) and Their Upstream m6A Regulator, Together with the Effect of Target Gene(s) in Drug Response
The target genes involved in drug-target interaction (such as drug-metabolizing enzymes, drug transporters and therapeutic targets) and drug-mediated cell death signaling (including modulating DNA damage and repair capacity, escaping from drug-induced apoptosis, autophagy, cellular metabolic reprogramming, oncogenic bypass signaling, cell microenvironment, cell stemness, etc.) could be regulated by m6A regulator(s) and affected their corresponding drug response. You can browse detailed information on drug-related target gene(s) mediated by m6A regulators.
Vascular endothelial growth factor A (VEGFA)
Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Vascular endothelial growth factor A (VEGFA) is a therapeutic target for Faricimab. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of Faricimab through regulating the expression of Vascular endothelial growth factor A (VEGFA). [1], [2]
Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Vascular endothelial growth factor A (VEGFA) is a therapeutic target for Faricimab. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Faricimab through regulating the expression of Vascular endothelial growth factor A (VEGFA). [1], [2]
Methyltransferase-like 3 (METTL3)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Vascular endothelial growth factor A (VEGFA) is a therapeutic target for Faricimab. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Faricimab through regulating the expression of Vascular endothelial growth factor A (VEGFA). [1], [2]
References
Ref 1 m6A methylated EphA2 and VEGFA through IGF2BP2/3 regulation promotes vasculogenic mimicry in colorectal cancer via PI3K/AKT and ERK1/2 signaling. Cell Death Dis. 2022 May 21;13(5):483. doi: 10.1038/s41419-022-04950-2.
Ref 2 Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration. Retina. 2006 Oct;26(8):859-70. doi: 10.1097/01.iae.0000242842.14624.e7.